Greenwoods Asset Management (HK)’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Greenwoods Asset Management (HK)’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-68,265	Closed	-$8.32M	–	30
2025 Q4	$8.32M	Sell	68,265 -486,750	-88%	-$55.8M	0.21%	26
2025 Q3	$55.6M	Buy	+555,015	New	+$50M	1.25%	18
2024 Q4	–	Sell	-70,400	Closed	-$6.96M	–	41
2024 Q3	$6.96M	Sell	70,400 -57,400	-45%	-$5.64M	0.22%	25
2024 Q2	$11.8M	Hold	127,800	–	–	0.31%	21
2024 Q1	$12.1M	Sell	127,800 -56,600	-31%	-$5.25M	0.38%	24
2023 Q4	$16.5M	Buy	+184,400	New	+$13.7M	0.59%	17
2023 Q1	–	Sell	-144,339	Closed	-$12M	–	36
2022 Q4	$12M	Sell	144,339 -83,500	-37%	-$6.76M	0.74%	18
2022 Q3	$18.1M	Sell	227,839 -125,000	-35%	-$10.5M	1.23%	15
2022 Q2	$26.2M	Buy	352,839 +295,153	+512%	+$22.2M	1.17%	17
2022 Q1	$5.18M	Buy	+57,686	New	+$5.33M	0.22%	27

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Greenwoods Asset Management (HK)'s XBI Position: Q1 2026 in Review

Greenwoods Asset Management (HK) sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 68,265 shares — an estimated $8.32M sold.

Greenwoods Asset Management (HK) first reported a position in XBI in Q1 2022 and held it in 10 quarters. The position peaked at $55.6M in Q3 2025. 815 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Greenwoods Asset Management (HK) reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
Greenwoods Asset Management (HK) sold 68,265 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $8.32M.
Greenwoods Asset Management (HK) first reported a position in State Street SPDR S&P Biotech ETF in Q1 2022 and held it in 10 quarters.
Greenwoods Asset Management (HK)'s State Street SPDR S&P Biotech ETF position peaked at $55.6M in Q3 2025.
815 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Greenwoods Asset Management (HK)'s 13F filing for Q1 2026, filed 8 May 2026.